BELLUS Health Inc. (BLU) News

BELLUS Health Inc. (BLU): $11.63

1.26 (+12.15%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BLU to Watchlist
Sign Up

Industry: Biotech


Ranked

of 402

in industry

Filter BLU News Items

BLU News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest BLU News From Around the Web

Below are the latest news stories about BELLUS Health Inc that investors may wish to consider to help them evaluate BLU as an investment opportunity.

LifeSci Capital Keeps Their Buy Rating on BELLUS Health (BLU)

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on BELLUS Health (BLU – Research Report) on January 24 and set a price target of $17.00. The company's shares closed last Wednesday at $5.90. According to TipRanks.com, Slutsky is ranked 0 out of 5 stars with an average return of -4.8% and a 34.8% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences, Ventyx Biosciences, and Sierra Oncology. The word on The Street in general, suggests a Strong Buy analyst consensus rating for BELLUS Health with a $16.33 average price target, representing a 169.5% upside. In a report issued on January 25, H.C.

Howard Kim on TipRanks | January 27, 2022

BELLUS Shares Have More Room to Run, Says Analyst

The week started in the best possible way for BELLUS Health (BLU) stock. While the main indexes bled in Monday’s session, BLU shares took the up escalator, surging by 48% following the announcement of positive clinical trial results. The company is testing lead candidate BLU-5937 as a potential therapy for refractory chronic cough (RCC). Topline results from the Phase 2b SOOTHE study of the P2X3 inhibitor showed the drug made a statistically meaningful difference; after 28 days of treatment there was a significant improvement to RCC patients' daily cough frequency, with a placebo-adjusted cough reduction of 34.4% in the 50mg cohort and a 34.2% drop in the 200mg group.

Marty Shtrubel on TipRanks | December 14, 2021

BELLUS Health (BLU) Receives a Buy from LifeSci Capital

In a report released yesterday, Sam Slutsky from LifeSci Capital maintained a Buy rating on BELLUS Health (BLU – Research Report), with a price target of $18.00. The company's shares closed last Monday at $8.30. According to TipRanks.com, Slutsky is a 3-star analyst with an average return of 6.1% and a 38.6% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences, Ventyx Biosciences, and Sierra Oncology. Currently, the analyst consensus on BELLUS Health is a Strong Buy with an average price target of $16.00, implying a 92.8% upside from current levels.

Christine Brown on TipRanks | December 14, 2021

BELLUS Health (BLU) Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Andrew Fein maintained a Buy rating on BELLUS Health (BLU – Research Report) today and set a price target of $14.00. The company's shares closed last Monday at $8.63. According to TipRanks.com, Fein is a 4-star analyst with an average return of 6.7% and a 40.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Deciphera Pharmaceuticals, and Global Blood Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for BELLUS Health with a $15.75 average price target, implying a 99.1% upside from current levels.

Catie Powers on TipRanks | December 13, 2021

ARNA Stock Alert: The Pfizer Deal That Has Arena Pharmaceuticals Rocketing Today

Arena Pharmaceuticals (ARNA) stock is flying higher on Monday thanks to a huge $6.7 billion acquisition deal with Pfizer (PFE).

William White on InvestorPlace | December 13, 2021

BLU Stock Alert: The Study Data That Has BELLUS Health Blasting Higher Today

BELLUS Health (BLU) stock is rocketing higher on Monday and it's all thanks to data from a Phase 2b clinical trial of BLU-5937.

William White on InvestorPlace | December 13, 2021

NES, WTTR: The Deal That Has Penny Stock Nuverra Environmental Solutions Skyrocketing Today

Nuverra Environmental (NES) stock is surging higher on Monday following news of a massive deal with Select Energy Services (WTTR).

William White on InvestorPlace | December 13, 2021

Analysts Offer Insights on Healthcare Companies: BELLUS Health (BLU) and AstraZeneca (AZN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BELLUS Health (BLU – Research Report) and AstraZeneca (AZN – Research Report). BELLUS Health (BLU) RBC Capital analyst Gregory Renza maintained a Buy rating on BELLUS Health today and set a price target of $11.00. The company's shares closed last Monday at $5.40. According to TipRanks.

Catie Powers on TipRanks | December 7, 2021

BELLUS Health (BLU) Receives a Buy from RBC Capital

In a report issued on November 15, Gregory Renza from RBC Capital maintained a Buy rating on BELLUS Health (BLU – Research Report), with a price target of $9.00. The company's shares closed last Monday at $6.15. According to TipRanks.com, Renza is a 1-star analyst with an average return of -1.1% and a 30.3% success rate. Renza covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Verrica Pharmaceuticals, and Inovio Pharmaceuticals. BELLUS Health has an analyst consensus of Strong Buy, with a price target consensus of $10.96, representing a 78.8% upside.

Brian Anderson on TipRanks | November 23, 2021

7 Biotech Penny Stocks With Huge Catalysts Coming in 2022

With a new year fast approaching, these biotech penny stocks may benefit from the shifting winds in the broader healthcare market.

Josh Enomoto on InvestorPlace | October 14, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5669 seconds.